Weekly Biotech Catalysts

Every Sunday: the coming week of FDA decision dates, Phase 2 and 3 trial completions and earnings, plus the past week of delays, discontinuations, FDA decisions and new timelines from SEC filings.

Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 27–Oct 4, 2026)

September 27, 2026 ·

No FDA decision dates fall in this week, so the calendar belongs to trials: seven company-led studies have estimated primary completion dates, among them IBRX’s BCG combination in bladder cancer, ARWR’s ARO-DIMERPA in mixed hyperlipidemia and JAZZ’s zanidatamab combination. On the financing side, VKTX filed $275M of convertible notes, and it was also last week’s […]

Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 20–Sep 27, 2026)

September 20, 2026 ·

Here’s what’s on the biotech calendar for September 20–September 27: 2 FDA decision dates, 1 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-09-22 IONS — NDA 2026-09-26 MIRM — NDA 🧪 Trial Catalysts & Milestones CRDL, 2026-09-21: CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) […]

Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 13–Sep 20, 2026)

September 13, 2026 ·

Here’s what’s on the biotech calendar for September 13–September 20: 1 FDA decision dates, 2 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-09-18 NUVL — adult patients with locally advanced or metastatic ROS1-posi NDA 🧪 Trial Catalysts & Milestones VRTX, 2026-09-17: An Efficacy, […]

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.